Network analysis of SRC-1 reveals a novel transcription factor hub which regulates endocrine resistant breast cancer.
Alacoque L BrowneSara CharmsazDamir VarešlijaAilis FaganNicola CosgroveSinéad CocchigliaSiobhan PurcellElspeth WardFiona BaneLance HudsonArnold D HillJason S CarrollAisling M RedmondLeonie S YoungPublished in: Oncogene (2018)
Steroid receptor coactivator 1 (SRC-1) interacts with nuclear receptors and other transcription factors (TFs) to initiate transcriptional networks and regulate downstream genes which enable the cancer cell to evade therapy and metastasise. Here we took a top-down discovery approach to map out the SRC-1 transcriptional network in endocrine resistant breast cancer. First, rapid immunoprecipitation mass spectrometry of endogenous proteins (RIME) was employed to uncover new SRC-1 TF partners. Next, RNA sequencing (RNAseq) was undertaken to investigate SRC-1 TF target genes. Molecular and patient-derived xenograft studies confirmed STAT1 as a new SRC-1 TF partner, important in the regulation of a cadre of four SRC-1 transcription targets, NFIA, SMAD2, E2F7 and ASCL1. Extended network analysis identified a downstream 79 gene network, the clinical relevance of which was investigated in RNAseq studies from matched primary and local-recurrence tumours from endocrine resistant patients. We propose that SRC-1 can partner with STAT1 independently of the estrogen receptor to initiate a transcriptional cascade and control regulation of key endocrine resistant genes.
Keyphrases
- network analysis
- transcription factor
- tyrosine kinase
- genome wide identification
- genome wide
- mass spectrometry
- estrogen receptor
- gene expression
- end stage renal disease
- small molecule
- newly diagnosed
- bioinformatics analysis
- chronic kidney disease
- epithelial mesenchymal transition
- dna binding
- ejection fraction
- single cell
- hiv testing
- prognostic factors
- heat shock
- ms ms
- signaling pathway
- case control
- free survival
- quantum dots
- replacement therapy
- breast cancer risk